ClinicalTrials.gg
CompletedNCT05908240CP3Updated Oct 29, 2026

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

An interventional study of Care Coordinator Model in Psoriasis, Psoriatic Arthritis and Psoriatic Conditions, sponsored by University of Pennsylvania. Completed at 20 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Prevention

How we know

Updated Oct 29, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
603
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
27th of 159
603 · median 228
Started
2023
with 8 others
No phase
20 of 194
3 open now
Registered
157th of 194
by date
Lead sponsor
8 of 194
University of Pennsylvania

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 27th largest by enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2023, is one of 20 with no phase, and was the 157th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

Read the detailed description

Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.

03

Conditions studied

  • Psoriasis
  • Psoriatic Arthritis
  • Psoriatic Conditions
  • Cardiovascular Diseases

Browse trials for

04

In context

Arthritis, Psoriatic Reclassified

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's enrollment of 603 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.

Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide
  2. Male or female aged 40-75
  3. Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis

Exclusion criteria

Exclusion Criteria:

  1. Currently taking a prescription lipid lowering medication
  2. Pregnant or planning pregnancy in the next 6 months
  3. Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
603 participants (actual)

Study arms

  • Other
    Care Coordination

    Other: Care Coordinator Model

Interventions

  • OtherCare Coordinator Model

    A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.

07

What researchers measure

Primary outcomes

  1. Change in LDL

    Change in LDL cholesterol

    Time frame: 6 months

Secondary outcomes

  1. Addition of new medication

    Percent newly using lipid lowering, hypertension (HTN), or diabetes (DM) medications

    Time frame: 6 months

  2. Change in 10-year cardiovascular (CV) risk

    Change in predicted 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among patients with baseline 10-year risk greater than or equal to 5% measured by the American College of Cardiology ASCVD risk estimator tool for predicting percent risk for atherosclerotic cardiovascular disease.

    Time frame: 6 months

  3. 30% LDL reduction

    Percent with 7.5% to 20% risk who achieve a 30% or greater reduction in LDL on follow up testing

    Time frame: 6 months

  4. 50% LDL reduction

    Percent with greater than or equal to 20% risk who achieve LDL reduction of greater than or equal to 50%

    Time frame: 6 months

  5. LDL reduction under 100

    Percent who achieve LDL less than 100 mg/dL or non-HDL less than 130 mg/dL

    Time frame: 6 months

  6. Change in blood pressure

    Change in systolic blood pressure (mm Hg)

    Time frame: 6 months

  7. Change in cholesterol

    Change in total cholesterol (mg/dL)

    Time frame: 6 months

  8. Change in HDL

    Change in HDL cholesterol (mg/dL)

    Time frame: 6 months

  9. Change in non-HDL

    Change in non-HDL cholesterol (mg/dL)

    Time frame: 6 months

  10. Change in HbA1c

    Change in hemoglobin A1c level measured in percent.

    Time frame: 6 months

  11. Change in Weight

    Change in weight calculated by BMI (kg/m2)

    Time frame: 6 months

  12. Smoking status change

    Percent of patients who quit smoking measured by self-reported response to survey question.

    Time frame: 6 months

  13. Percent undergoing additional CV testing

    Percent undergoing additional cardiovascular (CV) risk testing such as stress test, coronary calcium score or related imaging.

    Time frame: 6 months

  14. Change in Body Surface Area (BSA) psoriasis severity

    Change in percent of body surface area affected by psoriasis will be assessed.

    Time frame: 6 months

  15. Change in Physicians Global Assessment (PGA) psoriasis severity

    Change in PGA score measured from 0-5 with 5 being the most severe psoriasis and 0 being the least severe.

    Time frame: 6 months

  16. Change in dermatology life quality index (DLQI)

    Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: 6 months

  17. Change in general health

    EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.

    Time frame: 6 months

  18. Change in reported psoriasis medication use

    Proportion of patients who have reported any change in medications taken for psoriatic disease measured through a patient reported survey.

    Time frame: 6 months

  19. Change in physical activity days active

    Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the number of days active for at least 30 minutes over the past month

    Time frame: 6 months

  20. Change in physical activity level

    Change in patient reported physcial activity level through the Physical Activity Questionnaire measuring the patient reported level of physical activity on a likert scale from seldom active to vigorously active.

    Time frame: 6 months

  21. Patient experience with Care Coordinator Model

    Patient experience with the care coordinator will be measured through the Patient Experience Survey with a likert scale from strongly agree to strongly disagree.

    Time frame: 6 months

08

Study locations

20 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Central Connecticut Dermatology Research
    Cromwell, Connecticut 06416, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Dawes Fretzin Clinical Research
    Columbus, Indiana 47201, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • AP Derm Clinical Research LLC
    Somerville, Massachusetts 02145, United States
  • MiSkinCenter
    Northville, Michigan 48167, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • SUNY Downstate
    Brooklyn, New York 11203, United States
  • Buffalo Medical Group
    Williamsville, New York 14221, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • City Dermatology
    Bensalem, Pennsylvania 19020, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Bellevue Dermatology Clinic
    Bellevue, Washington 98004, United States
  • Frontier Dermatology
    Mill Creek, Washington 98012, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Sep 2026, 38 months.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's 38 months is above that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 18, 2023
StartActual
Jun 15, 2023
Primary completionActual
Sep 12, 2026
CompletionActual
Oct 16, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Enrollment
520 (estimated)→603 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Enrollment 520 (estimated)→603 (actual)
    + 3 other changes: verification date, date precision and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05908240
Collaborators
National Psoriasis Foundation
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jun 15, 2023
Primary completion
Sep 12, 2026
Completion
Oct 16, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion